Crossmark Global Holdings’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $975K | Buy |
4,297
+117
| +3% | +$20.8K | 0.01% | 632 |
|
|
2026
Q1 | $721K | Sell |
4,180
-29
| -0.7% | -$5.38K | 0.01% | 713 |
|
|
2025
Q4 | $840K | Sell |
4,209
-659
| -14% | -$120K | 0.01% | 664 |
|
|
2025
Q3 | $762K | Buy |
4,868
+4
| +0.1% | +$635 | 0.01% | 724 |
|
|
2025
Q2 | $738K | Buy |
4,864
+8
| +0.2% | +$1.07K | 0.01% | 723 |
|
|
2025
Q1 | $731K | Sell |
4,856
-73
| -1% | -$12.2K | 0.01% | 716 |
|
|
2024
Q4 | $910K | Sell |
4,929
-66
| -1% | -$12.7K | 0.02% | 609 |
|
|
2024
Q3 | $984K | Sell |
4,995
-973
| -16% | -$202K | 0.02% | 617 |
|
|
2024
Q2 | $1.23M | Sell |
5,968
-57
| -0.9% | -$12.9K | 0.02% | 524 |
|
|
2024
Q1 | $1.63M | Buy |
6,025
+88
| +1% | +$21K | 0.03% | 477 |
|
|
2023
Q4 | $1.4M | Hold |
5,937
| – | – | 0.03% | 504 |
|
|
2023
Q3 | $1.16M | Sell |
5,937
-84
| -1% | -$17.2K | 0.03% | 538 |
|
|
2023
Q2 | $1.27M | Sell |
6,021
-42
| -0.7% | -$8.36K | 0.03% | 525 |
|
|
2023
Q1 | $1.22M | Sell |
6,063
-63
| -1% | -$14.3K | 0.03% | 524 |
|
|
2022
Q4 | $1.33M | Buy |
6,126
+82
| +1% | +$17.9K | 0.03% | 495 |
|
|
2022
Q3 | $1.19M | Sell |
6,044
-148
| -2% | -$31.9K | 0.03% | 503 |
|
|
2022
Q2 | $1.32M | Sell |
6,192
-260
| -4% | -$63.5K | 0.03% | 494 |
|
|
2022
Q1 | $1.83M | Sell |
6,452
-600
| -9% | -$185K | 0.04% | 445 |
|
|
2021
Q4 | $2.66M | Sell |
7,052
-4,345
| -38% | -$1.69M | 0.06% | 327 |
|
|
2021
Q3 | $4.7M | Sell |
11,397
-7,477
| -40% | -$3.11M | 0.11% | 203 |
|
|
2021
Q2 | $6.98M | Buy |
18,874
+228
| +1% | +$76.1K | 0.16% | 151 |
|
|
2021
Q1 | $5.4M | Sell |
18,646
-218
| -1% | -$60.6K | 0.13% | 173 |
|
|
2020
Q4 | $4.71M | Buy |
18,864
+519
| +3% | +$124K | 0.12% | 191 |
|
|
2020
Q3 | $4.15M | Buy |
18,345
+977
| +6% | +$203K | 0.12% | 193 |
|
|
2020
Q2 | $3.03M | Buy |
17,368
+1,294
| +8% | +$207K | 0.09% | 251 |
|
|
2020
Q1 | $2.03M | Buy |
16,074
+1,028
| +7% | +$154K | 0.07% | 283 |
|
|
2019
Q4 | $2.3M | Buy |
15,046
+271
| +2% | +$37.5K | 0.06% | 326 |
|
|
2019
Q3 | $1.96M | Sell |
14,775
-474
| -3% | -$63.6K | 0.06% | 360 |
|
|
2019
Q2 | $2.16M | Sell |
15,249
-6,896
| -31% | -$935K | 0.06% | 360 |
|
|
2019
Q1 | $3.22M | Buy |
22,145
+434
| +2% | +$57K | 0.09% | 252 |
|
|
2018
Q4 | $2.46M | Sell |
21,711
-2,133
| -9% | -$267K | 0.08% | 295 |
|
|
2018
Q3 | $3.21M | Sell |
23,844
-436
| -2% | -$53.8K | 0.08% | 275 |
|
|
2018
Q2 | $2.73M | Buy |
24,280
+70
| +0.3% | +$7.57K | 0.07% | 299 |
|
|
2018
Q1 | $2.58M | Sell |
24,210
-1,269
| -5% | -$137K | 0.07% | 347 |
|
|
2017
Q4 | $2.79M | Buy |
25,479
+1,730
| +7% | +$188K | 0.07% | 341 |
|
|
2017
Q3 | $2.56M | Buy |
+23,749
| New | +$2.44M | 0.07% | 349 |
|
|
2016
Q3 | $2.56M | Buy |
+23,749
| New | +$1.99M | 0.07% | 349 |
|
Other funds holding CRL
AI
Crossmark Global Holdings's CRL Position: Q2 2026 in Review
Crossmark Global Holdings increased its Charles River Laboratories (CRL) stake by 2.8% in Q2 2026, buying an estimated $20.8K and bringing the position to 4,297 shares worth $975K. The position accounts for 0.01% of the portfolio, ranked #632.
Crossmark Global Holdings first reported a position in CRL in Q3 2016 and has held it in 37 quarters since. The position peaked at $6.98M in Q2 2021. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Crossmark Global Holdings held 4,297 shares of Charles River Laboratories worth $975K as of Q2 2026.
- Crossmark Global Holdings bought 117 Charles River Laboratories shares in Q2 2026, an estimated $20.8K.
- Charles River Laboratories made up 0.01% of Crossmark Global Holdings's portfolio in Q2 2026, its #632 holding.
- Crossmark Global Holdings first reported a position in Charles River Laboratories in Q3 2016 and has held it in 37 quarters since.
- Crossmark Global Holdings's Charles River Laboratories position peaked at $6.98M in Q2 2021.
- 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.